Mylan MYL
-
UPDATE 1- Mylan settles patent suit over Sunovion's lung drug
May 24 (Reuters) - U.S. generic drug maker Mylan Inc settled a patent infringement suit with Sunovion Pharmaceuticals Inc, a unit of Dainippon Sumitomo Pharma Co, related to the Japanese drugmaker's...
-
Teva Lowers Year-End Forecast, but Shares Still Appear Undervalued
… term. In the United States, increased industry competitiveness for Paragraph IV patent challenges from companies like Mylan MYL has reduced Teva's historical benefit from these 180-day market exclusivity periods. Teva has missed certain big …
-
BRIEF - Moody's raises Mylan Inc rating to Ba1
May 23 (Reuters) - Moody's raises Mylan Inc corporate family rating to Ba1 from Ba2
-
Mylan : Execution, Valuation Discount Suggest Further Upside Ahead
By Alex Shadunsky : As Mylan ( MYL ) has quietly outperformed ..... the most recent case was MYL 's announcement earlier this month . On May 10, Mylan increased its EPS guidance ..... diluted earnings per share. Mylan 's previous guidance range …
-
U.S. FDA approves sale of generic Plavix
May 17 (Reuters) - U.S. health regulators approved on Thursday the sale of generic versions of the widely used blood clot preventer Plavix by Mylan Pharmaceuticals, Teva Pharmaceutical Industries Ltd and several other generic drugmakers.
-
New Morningstar Analyst Report - Hospira, Inc.
… market share and shareholder returns. Global, vertically integrated generic drug manufacturers like Teva, Sandoz, and Mylan MYL will continue to pursue generic injectable products, but we think Hospira's injectable manufacturing expertise and …
-
New Morningstar Analyst Report - Mylan , Inc.
Compared with its peers, Mylan 's less diversified operations increases ..... volatility in generic drug markets. Mylan faces considerable competition from ..... without more acquisitions. We estimate Mylan 's cost of equity at 11.5%.
-
New Morningstar Analyst Report - Teva Pharmaceutical Industries, Ltd.
… estimates, Teva, Sandoz (a subsidiary of Novartis NVS), Mylan MYL , and Watson WPI account for about half of all generics sales ..... followed by two generic competitor launches, most likely Mylan and Momenta, in 2014 with a third possible entrant by …
-
New Morningstar Analyst Report - Watson Pharmaceuticals Inc.
… avoided an aggressive acquisition strategy like Teva and Mylan , management has proven adept at finding niche generic ..... Teva TEVA, Sandoz (a subsidiary of Novartis NVS), and Mylan MYL . We estimate these four companies will comprise over 50 …
-
Mylan ([[ MYL ]] +1.9%) gets a bump higher after the generic-drug maker raised its FY12 earnings outlook earlier today. It now expects to earn between $2.45 - $2.55 per share. Street consensus is for ...
Mylan ( MYL +1.9% ) gets a bump higher after the generic-drug maker raised its FY12 earnings outlook earlier today. It now expects to …